Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
Purpose
The primary purpose of this research is to describe patient characteristics predictive of an imaging study positive for distant metastases in patients with castration-resistant prostate cancer and no known distant metastases.
Condition
- Castration-Resistant Prostate Cancer
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Written informed consent obtained prior to the initiation of study procedures. - Men ≥ 18 years of age. - Histologically documented prostatic adenocarcinoma. - History of Castration-Resistant Prostate Cancer.
Exclusion Criteria
- Known M1 disease. - Undergone imaging study for metastatic prostate cancer ≤ 3 months. - ECOG performance status ≥ 3. - Known malignant pleural effusions or ascites. - Current or prior treatment with investigational therapy for M0 Castration-Resistant Prostate Cancer (Taxotere (docetaxel), Provenge® (sipuleucel-T), Zytiga (abiraterone acetate), Xtandi (enzalutamide), Jevtana (cabazitaxel), or Xofigo (radium Ra 223 dichloride).
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Case-Only
- Time Perspective
- Prospective
More Details
- Status
- Terminated
- Sponsor
- Dendreon